Inmunoterapia en el tratamiento del cáncer de mama

Kelin Brizette Monterrozo Brán

doi:10.36314/cunori.v8i1.246

Authors

Kelin Brizette Monterrozo Brán Universidad de San Carlos de Guatemala

DOI:

https://doi.org/10.36314/cunori.v8i1.246

Keywords:

immunotherapy, treatment, breast cancer

Abstract

PROBLEM: Breast cancer is one of the most frequent oncological diseases in the world, and despite advances based on conventional treatments, such as surgery, radiotherapy and chemotherapy, patient survival is still limited. However, immunotherapy is a cutting-edge approach in the treatment of breast cancer. What makes patients with this pathology have new alternatives for their treatment. OBJECTIVE: To immunotherapy in the treatment of breast cancer. METHOD: A documentary research based on scientific literature on immunotherapy in the treatment of breast cancer was developed. RESULTS: Immunotherapy in the treatment of breast cancer is based on harnessing the patient's immune system to fight cancer cells, although not all patients respond equally and challenges remain, advances provide hope and additional therapeutic options for those patients who do not benefit from traditional treatments. CONCLUSION: Standardized care protocols need to be established for the identification, evaluation, and treatment of breast cancer patients who may benefit from immunotherapy.

Downloads

Download data is not yet available.

Author Biography

Kelin Brizette Monterrozo Brán, Universidad de San Carlos de Guatemala

Licenciatura en Ciencias Médicas del Centro Universitario de Oriente de la Universidad de San Carlos de Guatemala, Maestría en Administración Hospitalaria y Servicios de Salud del Centro Universitario de Oriente y Maestría en Investigación del Centro Universitario de Oriente.

References

Arango Prado, M. C. & Rodríguez-Padilla, C. (2016). Protagonismo del sistema inmune en el microambiente de los tumores malignos de la mama. Revista Cubana de Hematología, Inmunología y Hemoterapia, 32(2), 1-16.

https://revhematologia.sld.cu/index.php/hih/rt/printerFriendly/410/231

Chowell, D., Krishna, S., Becker, P. D., Cocita, C., Shu, J., Tan, X., Greenberg, P. D., Klavinskis, L. S., Blattman, J. N. & Anderson, K. S. (2015). TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 112(14), 1754-1762. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394253/ DOI: https://doi.org/10.1073/pnas.1500973112

Food and Drug Administration. (2019). FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. https://www.fda.gov/drugs/drug-approvals-anddatabases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locallyadvanced-or-metastatic-triple-negative

Food and Drug Administration. (2020). FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer.

https://www.fda.gov/drugs/drug-approvals-anddatabases/fda-approves-combination-pertuzumab-trastuzumab-andhyaluronidase-zzxf-her2-positive-breast-cancer

García, B. & Lage, A. (2006). Inmunosenescencia: implicaciones para la inmunoterapia de cáncer en los adultos mayores. Biotecnología Aplicada, 23(3), 186-193. https://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/2006/23/3/BA0023 03RV186-193.pdf

Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thurlimann, B. & Senn, H. J. (2011). Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Annals of Oncology, 22(8), 1736-1747. https://www.annalsofoncology.org/action/showPdf?pii=S0923- 7534%2819%2938414-5 DOI: https://doi.org/10.1093/annonc/mdr304

González-Mariño, M. A. (2023). Virus en el tratamiento de cáncer de mama. Ginecología y Obstetricia de México, 91(5), 344-365.

https://ginecologiayobstetricia.org.mx/articulo/virus-en-el-tratamiento-decancer-de-mam

Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., Hicks, D. G., Lester, S., Love, R., Mangu, P. B., McShane, L., Miller, K., Osborne, C. K., Paik, S., Perlmutter, J. & Wolff, A. C. (2010). American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Clinical Oncology, 28(16), 2784-2795. DOI: https://doi.org/10.1200/JCO.2009.25.6529

https://ascopubs.org/doi/pdf/10.1200/JCO.2009.25.6529?role=tab

Maycotte, P., Medina-Benítez, D., Ramírez-Torres, N., López-Muñoz, E., MendozaGarcía, A. V., Cortéz-Hernández, P. y Anaya-Ruiz, M. (2020). Diagnóstico molecular del cáncer de mama: implicaciones pronósticas y terapéuticas. Revista Médica del Instituto Mexicano del Seguro Social, 58(1), 62- 74. https://www.redalyc.org/journal/4577/457769373008/html/

Reyes, S. J., González, K. B., Rodríguez, C., Navarrete-Muñoz, C., Salazar, A. P., Villagra, A., Caglevic, C. y Hepp, M. I. (2020). Actualización general de inmunoterapia en cáncer. Revista Médica de Chile, 148(7), 970-982. https://dx.doi.org/10.4067/S0034-98872020000700970 DOI: https://doi.org/10.4067/S0034-98872020000700970

Sánchez Arenas, M. P. M., Álvarez-Díaz, C. J. y Durán Cárdenas, C. (2018). La técnica correcta para la exploración de mama. Revista de la Facultad de Medicina, 61(2), 44-50. http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0026- 17422018000200044&lng=es&tlng=es

Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., CoteMitchel Dowsett, R. J., Fitzgibbons, P. L., Hanna, W. M., Langer, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R. & Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology, 25(1), 118-145. DOI: https://doi.org/10.1200/JCO.2006.09.2775

https://ascopubs.org/doi/pdf/10.1200/JCO.2006.09.2775?role=tab